The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment

The implications of boosting Omalizumab treatment (OT) in patients with severe allergic asthma (SAA) remain unclear. The study aimed to explore and compare the 12-month effectiveness between continuous, at least 10-month OT (continuation group) and four-month boost of Omalizumab (boost group) in adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wei-Chang, Fu, Pin-Kuei, Chan, Ming-Cheng, Chin, Chun-Shih, Huang, Wen-Nan, Lai, Kuo-Lung, Wang, Jiun-Long, Hung, Wei-Ting, Wu, Yi-Da, Hsieh, Chia-Wei, Wu, Ming-Feng, Chen, Yi-Hsing, Hsu, Jeng-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916868/
https://www.ncbi.nlm.nih.gov/pubmed/33670157
http://dx.doi.org/10.3390/jcm10040707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916868/
https://www.ncbi.nlm.nih.gov/pubmed/33670157
http://dx.doi.org/10.3390/jcm10040707

Ejemplares similares